Avalyn Pharma Inc. (NASDAQ:AVLN) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Analysts give Avalyn Pharma a “Moderate Buy” consensus rating, with two buy, two strong-buy, one hold and one sell recommendation. The average 12-month price target is $60, above the stock’s reported $37.39 price.
• Institutional interest increased in the second quarter, including new positions from Montanova Capital valued at approximately $82.4 million and Braidwell LP worth about $26.4 million.
• Avalyn reported a quarterly loss of $0.98 per share, beating the consensus estimate of a $1.03 loss. Shares were up 5.5%, with the company valued at roughly $1.66 billion and trading near its 52-week high.

Shares of Avalyn Pharma Inc. (NASDAQ:AVLN - Get Free Report) have received an average rating of "Moderate Buy" from the six ratings firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $60.00.

AVLN has been the topic of several recent research reports. Wall Street Zen lowered shares of Avalyn Pharma from a "hold" rating to a "sell" rating in a report on Saturday, August 15th. Morgan Stanley boosted their price objective on Avalyn Pharma from $53.00 to $57.00 and gave the company an "overweight" rating in a report on Thursday, August 13th. Evercore initiated coverage on Avalyn Pharma in a research note on Tuesday, May 26th. They issued an "outperform" rating and a $51.00 target price on the stock. Guggenheim assumed coverage on Avalyn Pharma in a research report on Monday, May 25th. They set a "buy" rating and a $80.00 price target for the company. Finally, Jefferies Financial Group initiated coverage on Avalyn Pharma in a report on Monday, May 25th. They issued a "buy" rating and a $52.00 price target for the company.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp purchased a new stake in shares of Avalyn Pharma during the 2nd quarter worth about $1,321,000. Montanova Capital LLC purchased a new position in shares of Avalyn Pharma in the 2nd quarter valued at about $82,402,000. Braidwell LP acquired a new position in Avalyn Pharma in the 2nd quarter worth about $26,382,000. Finally, California State Teachers Retirement System acquired a new position in Avalyn Pharma in the 2nd quarter worth about $236,000.

Avalyn Pharma Trading Up 5.5%

Shares of NASDAQ:AVLN opened at $37.39 on Friday. The company has a current ratio of 33.12, a quick ratio of 33.12 and a debt-to-equity ratio of 0.04. Avalyn Pharma has a twelve month low of $24.15 and a twelve month high of $40.17. The stock has a 50 day simple moving average of $32.28. The firm has a market cap of $1.66 billion and a P/E ratio of -1.64.

Avalyn Pharma (NASDAQ:AVLN - Get Free Report) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.98) EPS for the quarter, beating the consensus estimate of ($1.03) by $0.05. Equities research analysts predict that Avalyn Pharma will post -3.81 earnings per share for the current fiscal year.

Avalyn Pharma Company Profile

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source